Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...
Leqembi Receives Positive Public Reimbursement Recommendation in Canada BioArctic announced that CDA-AMC has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for el...
GSK’s Shingrix prefilled syringe presentation approved in Canada GSK Canada announced that Health Canada has approved a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine) fo...
CDA-AMC recommends public reimbursement of LEQEMBI (lecanemab) for early Alzheimer’s disease Eisai Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive recommendation...
